1/1/2023 0 Comments Alejandra costamagna pdf![]() Participants were followed up at least every 6 months for incident cardiovascular and other serious clinical outcomes. All investigators and participants were masked to treatment assignment. ![]() Randomisation was done by a computer-generated random code with stratification by site. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1♵ mg) or placebo. This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control. Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A 1c (HbA 1c) concentrations. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |